Evolving therapeutic landscape of primary biliary cholangitis: A review

doi:10.4254/wjh.v17.i7.107223

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (21)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-1)

Sum=18

Jul 27, 2025 (publication date) through Jul 25, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Hepatol. Jul 27, 2025; 17(7): 107223
Published online Jul 27, 2025. doi: 10.4254/wjh.v17.i7.107223

Evolving therapeutic landscape of primary biliary cholangitis: A review

Natalie E Mitchell, Shu-Yen Chan, David Jerez Diaz, Nida Ansari, Junseo Lee, Patrick Twohig

Natalie E Mitchell, Junseo Lee, Patrick Twohig, Department of Gastroenterology & Hepatology, University of Rochester Medical Center, Rochester, NY 14682, United States

Shu-Yen Chan, Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL 60630, United States

David Jerez Diaz, Department of Internal Medicine, Florida State University, Sarasota Memorial Hospital, Sarasota, FL 34239, United States

Nida Ansari, Department of Internal Medicine, St. Joseph’s University Medical Center, Paterson, NJ 07504, United States

Author contributions: Mitchell NE, Chan SY, Jerez Diaz D, Ansari N, Lee J, and Twohig P contributed equally to this work; Twohig P designed the overall concept and outline of the manuscript; Mitchell NE, Chan SY, Jerez Diaz D, Ansari N, Lee J conducted the literature review and drafted the manuscript; Mitchell NE and Twohig P made critical revisions; all authors prepared the draft and approved the submitted version.

Conflict-of-interest statement: All authors declare no conflict of interests for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Patrick Twohig, Assistant Professor, FRCPC, Department of Gastroenterology & Hepatology, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14682, United States. patrick_twohig@urmc.rochester.edu

Received: March 19, 2025
Revised: April 23, 2025
Accepted: June 9, 2025
Published online: July 27, 2025
Processing time: 129 Days and 10.1 Hours

Core Tip

Core Tip: Primary biliary cholangitis (PBC) is a chronic, progressive, cholestatic autoimmune liver disease predominantly affecting middle-aged women. Novel therapeutic strategies have emerged in recent years, providing promising treatment options for more refractory disease. This comprehensive review provides an overview of existing and new treatment therapies for PBC.